Kinnate Biopharma (KNTE) Short Interest Ratio & Short Volume

Short interest is the volume of Kinnate Biopharma shares that have been sold short but have not yet been covered or closed out. As of March 15th, investors have sold 465,600 shares of KNTE short. 2.01% of Kinnate Biopharma's shares are currently sold short. Learn More on Kinnate Biopharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KNTE shares currently have a short interest ratio of 1.0. Learn More on Kinnate Biopharma's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Kinnate Biopharma: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.01% of Kinnate Biopharma's floating shares are currently sold short.

Kinnate Biopharma saw a drop in short interest in March. As of March 15th, there was short interest totaling 465,600 shares, a drop of 43.6% from the previous total of 825,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Kinnate Biopharma currently has issued a total of 47,220,000 shares. Some of Kinnate Biopharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Kinnate Biopharma currently has a public float of 23,170,000 shares.

2.01% of Kinnate Biopharma's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Kinnate Biopharma: NGM Biopharmaceuticals, Inc. (4.52%), LianBio (0.36%), Inotiv, Inc. (4.07%), Karyopharm Therapeutics Inc. (19.94%), Cardiol Therapeutics Inc. (0.53%), Repare Therapeutics Inc. (2.39%), Biodesix, Inc. (1.12%), Outset Medical, Inc. (16.17%), So-Young International Inc. (0.07%), Genetron Holdings Limited (0.08%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks.

Short selling KNTE is an investing strategy that aims to generate trading profit from Kinnate Biopharma as its price is falling. KNTE shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Kinnate Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KNTE, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KNTE, twice per month. The most recent reporting period available is March, 15 2024.